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Maintenance of skeletal muscle mass relies on the
dynamic balance between anabolic and catabolic
processes and is important for motility, systemic
energyhomeostasis, andviability.We identifieddirect
target genes of the glucocorticoid receptor (GR) in
skeletal muscle, i.e., REDD1 and KLF15. As well as
REDD1, KLF15 inhibits mTOR activity, but via a
distinct mechanism involving BCAT2 gene activation.
Moreover, KLF15 upregulates the expression of the
E3 ubiquitin ligases atrogin-1 and MuRF1 genes and
negatively modulates myofiber size. Thus, GR is
a liaison involving a variety of downstream molecular
cascades toward muscle atrophy. Notably, mTOR
activation inhibits GR transcription function and effi-
ciently counteracts thecatabolicprocessesprovoked
by glucocorticoids. This mutually exclusive crosstalk
betweenGR andmTOR, a highly coordinated interac-
tion between the catabolic hormone signal and the
anabolic machinery, may be a rational mechanism
for fine-tuning of muscle volume and a potential ther-
apeutic target for muscle wasting.
INTRODUCTION
Muscle comprises40% of body mass and contributes not only
to the structure and movement of the body but also to nutrient
storage and supply (Matthews, 1999). In adult mammals, skeletal
muscle hypertrophy/atrophy is characterized by an increase/
decrease in the size (as opposed to the number) of individual
myofibers, respectively. The control of muscle mass is believed170 Cell Metabolism 13, 170–182, February 2, 2011 ª2011 Elsevier Into be determined by a dynamic balance between anabolic and
catabolic processes (Hoffman and Nader, 2004). Mammalian
target of rapamycin (mTOR) is a crucial component of the
anabolic machinery for protein synthesis. mTOR consists of
two complexes: mTORC1, which includes Raptor, signals to
S6K and 4E-BP1, controls protein synthesis, and is rapamycin
sensitive; and mTORC2, which includes Rictor, signals to Akt,
and is rapamycin insensitive. mTORC1 integrates four major
signals: growth factors, energy status, oxygen, and amino acids,
especially branched-chain amino acids (BCAAs). Prototypically,
insulin/IGF-1 activates mTOR via the PI3K-Akt pathway (Sen-
gupta et al., 2010). It is currently considered that mTORC1,
and not mTORC2, is essential for the maintenance of muscle
mass and function (Bentzinger et al., 2008; Risson et al., 2009).
Protein degradation in skeletal muscle cells is essentially medi-
ated by the activity of two conserved pathways: the ubiquitin-
proteasomal pathway and the autophagic/lysosomal pathway
(Sandri, 2008). The ubiquitin-proteasomal pathway is respon-
sible for the turnover of the majority of soluble and myofibrillar
muscle proteins. The activity of this pathway is markedly
increased in atrophying muscle due to the transcriptional activa-
tion of a set of E3 ligase-encoding genes, e.g., atrogin-1 and
MuRF1 (Glass, 2003; Sandri et al., 2004). Autophagy also plays
an important role in the degradation of skeletal muscle, and is
indicated to be a consequence of an ordered transcriptional
program involving a battery of genes, e.g., LC3 and Bnip3
(Mizushima et al., 2008). These positive and negative pathways
are balanced in a highly coordinated manner for the determina-
tion of myofiber size and total muscle volume; however, distor-
tion of this balance with a relative increase in degradation results
in the generalized decrease of myofiber size and muscle atrophy
(Hoffman and Nader, 2004). Pioneering studies demonstrated
that muscle atrophy is a result of active processes that are tran-
scriptionally controlled through the expression of a particular
gene set; the forkhead box O (FoxO) transcription factors arec.
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critical liaison molecules for protein degradation and autophagy
via the transcriptional regulation of, for example, atrogin-1,
MuRF1, LC3, and Bnip3 (Mammucari et al., 2007; Sandri et al.,
2004; Stitt et al., 2004; Zhao et al., 2007). In clear contrast, it is
evident that each disease has proper signaling pathways to
FoxOs and that other components of the cellularmachinery often
participate in the progression of atrophy (Moresi et al., 2010;
Suzuki et al., 2007). Therefore, for the development of therapies
against muscle atrophy, it should be addressed how the tran-
scriptional program triggered by a particular atrophy pathway
is orchestrated and how the balance of muscle protein synthesis
and degradation is distorted in each disease.
Adrenal glucocorticoids produce their actions via a signal
pathway involving the ubiquitously expressed glucocorticoid
receptor (GR), a prototypic member of the nuclear receptor
superfamily, which acts as a ligand-dependent transcription
factor. Upon binding glucocorticoids, GR translocates into the
nucleus and binds to the glucocorticoid response element
(GRE) in the promoters of target genes. The binding of liganded
receptors to target DNA is followed by the recruitment of medi-
ators and coactivators to the proximity of GRE, resulting in the
recruitment of RNA polymerase II (RNAPII) to nearby transcrip-
tion start sites and the activation of transcription (Evans, 2005;
Meijsing et al., 2009). In skeletal muscle, glucocorticoids elicit
a variety of biological actions in the metabolism of glucose,
lipids, and proteins and contribute to metabolic homeostasis
(Munck et al., 1984). On the other hand, the prolonged overse-
cretion or exogenous administration of glucocorticoid gives
rise to undesirable effects including muscle atrophy (Munck
et al., 1984). Although many studies addressed the mechanism
of glucocorticoid-induced muscle atrophy, how the glucocorti-
coid-GR system generates the functional coupling between
metabolic regulation and volume adjustment in skeletal muscle
remains unsolved. Of note, many pathological conditions char-
acterized by muscle atrophy, e.g., sepsis, cachexia, starvation,
metabolic acidosis, and severe insulinopenia, are associated
with an increase in circulating glucocorticoid levels. Adrenalec-
tomy or treatment with the GR antagonist RU486 attenuates
muscle atrophy in sepsis, cachexia, starvation, and severe
insulinopenia (Menconi et al., 2007; Schakman et al., 2008).
Moreover, endogenous glucocorticoids were shown to be
essential for muscle atrophy in acute diabetic rodents (Hu
et al., 2009). Together, understanding the glucocorticoid-medi-
ated regulation of metabolism-volume coupling in muscle is
increasingly important for the management of not only muscle
atrophy but also these wasting/metabolic disorders.
Typically, glucocorticoid-induced muscle atrophy is charac-
terized by fast-twitch type II glycolytic muscle fiber loss with
reduced or no impact on type I fibers. The mechanism of such
fiber specificity is yet unknown. Previous reports suggested
that the glucocorticoid-GR system has antianabolic and
catabolic effects and promotes degradation via the induction
of a set of genes including atrogin-1, MuRF1, and myostatin
(Menconi et al., 2007; Schakman et al., 2008). Although the
involvement of FoxO transcription factors is reported in the
gene regulation of atrogin-1 and MuRF1 under the presence of
excess glucocorticoids (Sandri et al., 2004; Stitt et al., 2004),
the biochemical role of GR in the transcriptional regulation ofCell Mmuscle tissue has not yet been determined. Therefore, we inves-
tigated how GR-mediated gene expression coordinately modu-
lates antianabolic and catabolic actions to understand the func-
tional coupling of metabolism and volume regulation in muscle.
In the present study, we identified REDD1 and KLF15 genes as
direct targets of GR. REDD1 is known to be induced by various
stressors, including glucocorticoid, and to inhibit mTOR activity
via the sequestration of 14-3-3 and the increase of TSC1/2
activity (Wang et al., 2006; DeYoung et al., 2008). We clearly
identified the functional GRE via the promoter analysis of
REDD1 gene. On the other hand, KLF15 is a recently discovered
transcription factor that is involved in several metabolic
processes in skeletal muscle; e.g., KLF15 transcriptionally upre-
gulates the gene expression of branched-chain aminotrans-
ferase 2 (BCAT2), a mitochondrial enzyme catalyzing the first
reaction in the catabolism of BCAA to accelerate BCAAdegrada-
tion and alanine production in skeletal muscle (Gray et al., 2007).
Moreover, phenotypic analysis of cardiac-specific KLF15
knockout mice revealed marked left ventricular hypertrophy,
indicating the negative regulatory role of KLF15 on muscle
mass (Fisch et al., 2007). We here demonstrated that KLF15
participates in muscle catabolism via the transcriptional regula-
tion of atrogin-1 and MuRF1. Moreover, KLF15 affects mTOR
through BCAA degradation and negatively modulates myofiber
size. mTOR activation inhibits GR-mediated transcription by
suppressing GR recruitment onto target genes, strongly sug-
gesting a mutually exclusive crosstalk between mTOR and GR.
Pharmacological activation of mTOR with BCAA attenuated
GR-mediated gene expression, leading to the substantial resto-
ration of muscle in glucocorticoid-treated rats. We, therefore,
indicate the critical importance of the interaction of GR and
mTOR in the regulation of metabolism-volume coupling in skel-
etal muscle.
RESULTS
REDD1 and KLF15 Are Target Genes of GR in Skeletal
Muscle
GR levels were relatively high in type II-rich gastrocnemius and
tibialis anterior muscles compared to type I-rich soleus muscle
in rats (Figure 1A). Figure 1B illustrates the comparison of the
effects of a 3 hr treatment with dexamethasone (DEX) on
mRNA expression of various genes between the gastrocnemius
and soleus muscles. Hormonal induction of mRNA expression of
REDD1, atrogin-1, MuRF1, KLF15, FoxO1, FoxO3, and myosta-
tin, as well as the well-known GR target gene FKBP5 (Yoshikawa
et al., 2009), was observed in bothmuscles, but to a lesser extent
in the soleus muscle. Among the genes induced by DEX at 3 hr
(Figure 1B), the promoter regions of MuRF1 (Waddell et al.,
2008) and myostatin (Ma et al., 2001), but not atrogin-1 (Sandri
et al., 2004), contain functional GREs. In addition, REDD1 and
KLF15 were also considered as candidates of GR target genes
(see the Supplemental Information available online).
Concerning KLF15, we showed, in gastrocnemius muscle and
L6 myotubes but not in liver, that KLF15 mRNA and protein
expression was induced in a GR-dependent manner (Figure 2A).
The promoter region spanning from 4676 to +116 of KLF15
gene was not responsive to DEX; however, the activity of the
region spanning 2108 to +1331 was induced by DEX, andetabolism 13, 170–182, February 2, 2011 ª2011 Elsevier Inc. 171
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Figure 1. GR Protein Expression and Glucocorticoid-Dependent
mRNAExpression of Atrophy-Related Genes in Rat SkeletalMuscles
(A) GR protein levels in rat gastrocnemius (Gas), soleus (Sol), and tibialis ante-
rior (Tib). Left, representative immunoblots. Right, quantified protein levels of
GR relative to GAPDH (n = 9).
(B) Induction of mRNA levels of atrophy-related genes by dexamethasone
(DEX). Expression levels of the indicated mRNA in the muscles from rats 3 hr
after intraperitoneal injection with DEX were assessed in quantitative RT-
PCR (qRT-PCR). Results are shown as fold induction to vehicle-treated rats
(n = 6).
(A and B) Error bars show SD. *p < 0.05, zp < 0.05 versus vehicle-treated rats.
Cell Metabolism
Crosstalk between GR and mTOR in Skeletal Musclethis induction was inhibited by a GR antagonist RU486. The
deletion and mutational analyses of KLF15 promoter indicated
that both upper GRE1 and lower GRE2 sites were functional
(Figures 2B and 2C). The transient transfection assays using
the reporter constructs conveying these minimal GRE sites
clearly showed that each GRE is independently functional (Fig-
ure 2D). A chromatin immunoprecipitation (ChIP) assay revealed
that both GRE-like sequences were targeted by GR and that
RNAPII was incorporated onto the coding region of KLF15
gene in the presence of DEX in L6 cells (Figure 2E). We also
confirmed the DEX-dependent recruitment of endogenous GR
onto the KLF15 promoter in a skeletal muscle-specific manner
in vivo (Figure 2F). Similarly, we identified the functional GRE
on the REDD1 promoter region and confirmed REDD1 as a GR
target gene as well (Figure S1).KLF15 Transactivates atrogin-1 and MuRF1 Genes
Next,we studied the alteration in thegene expressionprofile after
the direct injection of a KLF15-expressing adenovirus into the rat
tibialis anterior muscle. The exogenous expression of KLF15
increased KLF15 protein levels by approximately 5-fold (Fig-
ure 3A) and significantly induced mRNA expression of its target
gene BCAT2 as anticipated (Figure 3B). Moreover, mRNA
expression of atrogin-1, MuRF1, FoxO1, and FoxO3 was stimu-
lated by KLF15 (Figure 3B). We then focused on atrogin-1 and
MuRF1 and asked whether the DEX-mediated induction of their
mRNA expression was dependent on KLF15. For that purpose,
we tested the effect of knocking down the expression of GR or
KLF15 on mRNA expression of KLF15, atrogin-1, and MuRF1172 Cell Metabolism 13, 170–182, February 2, 2011 ª2011 Elsevier Inas well as another GR target gene REDD1 as a control. In L6
myoblasts, GR knockdown diminished the DEX-dependent
mRNA induction of all of these GR target genes. However,
KLF15 knockdown affected that of atrogin-1 and MuRF1 but
not REDD1 (Figure 3C). These results strongly indicate the critical
involvement of the GR-KLF15 cascade in the DEX-mediated up-
regulation of atrogin-1 and MuRF1 gene expression. To address
the role of KLF15 in the transcriptional regulation of atrogin-1 and
MuRF1, we constructed luciferase reporter plasmids driven by
the promoter of rat atrogin-1 or MuRF1, and tested the effect of
the exogenousexpression ofKLF15 in L6myoblasts. The expres-
sion of the reporter genes was upregulated in a KLF15-depen-
dent manner (Figure 3D). Since the promoter regions of atrogin-
1 and MuRF1 contain a number of putative KLF15 recognition
sites, we performed ChIP analyses; both promoters had multiple
KLF15 binding sites and some of them were located in the prox-
imity of FoxO binding sites and GRE (Figure 3E), and at least one
of these KLF15 sites of each promoter recruited KLF15 in a DEX-
dependent manner in vivo as well (Figure 3F). Note that atrogin-1
andMuRF1 were originally identified as FoxO target genes (San-
dri et al., 2004;Waddell et al., 2008) and thatKLF15 inducedFoxO
mRNA expression (Figure 3B). Indeed, the combination of KLF15
and FoxO significantly enhanced the promoter activity of atrogin-
1 and MuRF1 when compared to their individual effects (Fig-
ure 3G).Moreover, the direct injection of the adenovirus express-
ing constitutively active FoxO1 or KLF15 significantly increased
atrogin-1 and MuRF1 mRNA expression, and the expression of
both resulted in synergistic or additive effects in tibialis anterior
(Figure 3H). Therefore, it is likely that KLF15 and FoxO transcrip-
tion factors cooperatively upregulate the expression of atrogin-1
and MuRF1 genes.
GR-KLF15 Axis Modulates BCAA Metabolism and mTOR
Activity
Next,westudied theeffectsof glucocorticoids,GR,andKLF15on
BCAT2 andBCAAcatabolism in skeletal muscle cells. In gastroc-
nemius muscle, mRNA expression of KLF15 preceded that of
BCAT2 after treatment with DEX (Figure 4A). Overexpression of
KLF15 increased theBCAT2 promoter-luciferase reporter activity
(Figure 4B). Moreover, DEX-induced BCAT2 promoter activation
was inhibited by either RU486 or siKLF15 (Figure 4C), indicating
that KLF15 is mandatory for GR-mediated BCAT2 gene activa-
tion. BCAT2 enzyme activity was stimulated by DEX, and this
effect was abolished in the presence of RU486 (Figure 4D). In ti-
bialis anteriormuscle andL6myotubes, theadenovirus-mediated
exogenous expression of KLF15 significantly induced BCAT2
enzyme activity even in the absence of DEX (Figure 4E).
The measurement of intracellular amino acid levels clearly
revealed the accelerated catabolism of BCAA by KLF15 in
myotubes; the exogenous expression of KLF15 decreased the
levels of Val, Leu, and Ile, with a reciprocal increase in Ala and
Glu without significant alterations in, for example, Gly, Trp, Gln,
Tyr, and Phe, in L6myotubes (Figure 4F). Amino acids, especially
BCAA, are believed to activate mTOR and to increase in associ-
ation with Rheb-mTOR (Sancak et al., 2010). We showed that
overexpression of KLF15 in C2C12 myotubes suppressed
mTORactivity as demonstrated by thedecrease in thephosphor-
ylated form of S6K1. Moreover, mTOR activity was comple-
mented by the addition of excess BCAA (Figure 4G). Of note,c.
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Figure 2. Identification of KLF15 as a Direct GR Target Gene
(A) GR-dependent mRNA (left) and protein (right) expression of KLF15 in L6 myotubes treated with DEX and RU486 for 6 hr and in DEX-treated rat gastrocnemius
(see legend for Figure 1B).
(B) Identification of GREs in rat KLF15 promoter. Left, schematic of rat KLF15 promoter-luciferase reporter constructs. Positions of the primers for chromatin
immunoprecipitation (ChIP) in (E) and (F) are shown. Right, GR-dependent activation of rat KLF15 promoter-reporter genes. COS-7 cells were transfected
with the reporter constructs and 100 ng of GR expression plasmid and treated with DEX and RU486 for 18 hr.
(C) GR-dependent activation of rat KLF15 promoter-reporter genes in L6 myoblasts treated with DEX and RU486 for 18 hr.
(D) GR-dependent activation of reporter genes containing KLF15 promoter GREs. L6 myoblasts were transfected with the luciferase reporter constructs contain-
ing the GREs from rat KLF15 with GR expression plasmid and treated with DEX and RU486 for 18 hr.
(E) DEX-dependent recruitment of GR and RNAPII onto rat KLF15 gene. L6 myotubes treated with 1 mM DEX for 2 hr were subjected to ChIP.
(F) Skeletal muscle-specific recruitment of GR onto rat KLF15 gene by DEX. DEX-treated rat gastrocnemius (Gas) and liver (see legend for Figure 1B) were
subjected to ChIP.
(A–F) Error bars show SD (n = 5). *p < 0.05.
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Figure 3. Transcriptional Regulation of Atrogenes by KLF15 and FoxOs
(A and B) KLF15-dependent mRNA expression of atrophy-related genes. Recombinant adenovirus Ad-KLF15 was infected to rat tibialis anterior for 7 days.
(A) Immunoblot detection of ectopic KLF15. (B) qRT-PCR.
(C) Effects of knockdown of KLF15 or GR on DEX-dependent mRNA expression of atrophy-related genes. L6 myoblasts were transfected with control siRNA,
siRNA against KLF15, or siRNA against GR and treated with DEX for 18 hr.
(D) KLF15-dependent activation of rat atrogin-1 (left) and MuRF1 (right) promoter-reporter genes in L6 myoblasts.
(E) Mapping of the binding sites for KLF15, FoxOs, and GR in rat atrogin-1 and MuRF1 promoters. Top, putative binding sites identified in in silico promoter anal-
ysis (see the Experimental Procedures and the Supplemental Information). Bars indicate the positions of the primers for ChIP. Bottom, recruitment of KLF15 onto
rat atrogin-1 and MuRF1 promoters. L6 myotubes were infected with Ad-KLF15 for 5 days and subjected to ChIP using anti-KLF15 antibody.
(F) DEX-dependent recruitment of KLF15 onto rat atrogin-1 and MuRF1 promoters in rat gastrocnemius (see Figure 1B).
(G and H) Effects of FoxOs and KLF15 on rat atrogin-1 and MuRF1 promoter-reporter gene expression in L6 myoblasts (G) and on atrogin-1 and MuRF1 mRNA
expression in rat tibialis anterior (H). (G) Luciferase assay of L6myoblasts transfectedwith the reporter constructs with or without FoxO1 and/or KLF15 expression
plasmids. (H) qRT-PCR analysis of rat tibialis anterior expressing ectopic KLF15 and/or constitutive active FoxO1 (3AFoxO1) for 3 days.
(B–H) Error bars show SD (n = 5). *p < 0.05, zp < 0.05 versus vehicle-treated cells, yp < 0.05 versus mock-transfected cells, xp < 0.05 versus ChIP with normal IgG,
{p < 0.05 versus mock-infected rats.
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Crosstalk between GR and mTOR in Skeletal Musclethe diameter of C2C12 myotubes was shortened by KLF15 and
rescued by BCAA (Figure 4G). Moreover, exogenous KLF15
reduced mTOR activity with fiber type-independent atrophy in
the tibialis anterior muscle (Figure 4H). Taken together, these
data indicate that KLF15 is a liaisonmolecule for GR in the induc-
tion of atrogenes and the acceleration of BCAA catabolism and
mTOR repression to decrease myofiber size.
mTOR Affects GR-Mediated Transcriptional Regulation
Since little is known about how glucocorticoid-mediated cata-
bolic signal transduction is shut off, we next examined the effects
of mTOR blockade using rapamycin on GR-mediated gene
expression in L6 myotubes. Surprisingly, rapamycin significantly
enhanced the DEX-induced mRNA expression of a number of
GR target genes, including REDD1, atrogin-1, MuRF1, KLF15,
FoxOs, and FKBP5 (Figure 5A). These results strongly suggest
that mTOR blockade selectively enhances mRNA expression
of GR target genes, i.e., mTOR activation appears to have
a negative impact on GR-mediated gene expression. To further
address this negative modulation of GR function by mTOR, we
performed transient transfection assays using GR-responsive
KLF15 promoter-Luc and GRE-Luc reporter genes in L6
myoblasts. A constitutively active mutant of Rheb, RhebS16H,
which autonomously activates mTOR, repressed DEX-mediated
reporter gene activation, and rapamycin inhibited these negative
effects of RhebS16H (Figure 5B). Moreover, amajor endogenous
mTOR activator IGF-1 slightly enhanced S6K1 phosphorylation
and did not affect DEX-induced GRE-Luc expression when
cultured in amino acid-rich media. In clear contrast, in amino
acid-deprived media, DEX-dependent induction of GRE-Luc
was approximately doubled, and IGF-1 strongly phosphorylated
S6K1 and suppressed DEX-induced GRE-Luc expression (Fig-
ure 5C). These results indicated that, regardless of the upstream
pathways for mTOR activation, endogenous GR activity is nega-
tively controlled by mTOR in L6 myoblasts.
We then asked the underlying mechanisms for mTOR-medi-
ated GR suppression. To test whether mTOR-mediated GR
repression is via global protein synthesis downstream of
mTOR, we examined luciferase mRNA expression in transient
transfection assay using GRE-Luc reporter plasmid in the pres-
ence or absence of the protein synthesis inhibitor cycloheximide.
Cycloheximide did not influence on either GR-mediated GRE
activation or BCAA-mediated GR suppression (Figure 5D).
Therefore, BCAA inhibits the transcriptional effects of GR via
mTOR activation but not via de novo protein synthesis. Immuno-
blotting using L6 myotubes revealed that GR protein levels were
unaltered in the presence of DEX, BCAA, or rapamycin. Treat-
ment with DEX clearly promoted the nuclear translocation of
GR, and such a process was not affected by BCAA or rapamycin
(Figure 5E). Concerning the promoter regions spanning the puta-
tive GREs in KLF15 and REDD1, DEX-induced GR recruitment
was significantly enhanced by rapamycin, suggesting that
mTOR negatively influences the access of GR to these pro-
moters. Such an enhancement of GR promoter binding by rapa-
mycin was paralleled by RNAPII recruitment onto the coding
regions of KLF15 and REDD1 (Figure 5F). Thus, cellular mTOR
activity negatively modulates GR transcriptional function, most
possibly by altering the intranuclear behavior of GR. We finally
examined the effect of constitutive mTOR activation by studyingCell Mthe impact of adeno-associated virus-driven RhebS16H expres-
sion on S6K1 activity and the gene expression profile of the tibia-
lis anterior muscle from DEX-treated rats. RhebS16H-injected
muscle had elevated levels of S6K1 phosphorylation and signif-
icant decreases in the induction response to DEX of a number of
glucocorticoid-inducible genes, including REDD1, atrogin-1,
MuRF1, FoxOs, KLF15, and FKBP5, when compared to mock-
injected muscle (Figures 5G and 5H).
mTOR Activation Attenuates Glucocorticoid-Induced
Muscle Atrophy
It should be noted that numerous studies examined the effects of
BCAA on mTOR activity in glucocorticoid-induced atrophy
modelswithconflicting results, the reason forwhichmightbevari-
ations in theprotocols used in those in vivo studies (Menconi et al.,
2007; Schakman et al., 2008). We showed that the bolus admin-
istration of a BCAA cocktail via a gastric tube just before the peri-
toneal injection of DEX (Supplemental Information) resulted in
sufficient and reproduciblemTORactivation in thegastrocnemius
muscle; the phosphorylated form of S6K1 was increased at
30 min after BCAA administration and returned to the baseline
level after 90–180 min, even in the presence of DEX (Figure 6A).
We then tested the effects of DEX, BCAA, and rapamycin on the
protein levels and phosphorylation status of mTOR and its down-
stream effectors S6K1 and 4E-BP1 as well as Akt, the upstream
activator of mTOR, in the rat glucocorticoid-induced atrophy
model (5 day intraperitoneal DEX administration, see the Supple-
mental Information). In GR-rich gastrocnemiusmuscle, treatment
with DEX suppressed the phosphorylation of S6K1 and 4E-BP1,
without a significant alteration in p-Akt, indicating that DEX in-
hibited mTOR function in an Akt-independent fashion in this
model. In clear contrast, in either the soleus muscle or liver,
DEX treatment did not affect mTOR activity. When BCAA was
supplemented, the levels of p-S6K1 and p-4E-BP1 were effi-
ciently restored. Of note, rapamycin canceled these effects of
BCAA (Figure 6B). In this model, BCAA administration sup-
pressed the glucocorticoid-induced expression of REDD1, atro-
gin-1, MuRF1, KLF15, FoxOs, and FKBP5 mRNA (Figure 6C),
and there was a decrease in GR recruitment onto the promoters
of KLF15, REDD1,MuRF1, and FKBP5 (Figure 6D). BCAA admin-
istration also repressed the expression of BCAT2, GLUT4, Bnip3,
and LC3 mRNA, and treatment with rapamycin inhibited the
effects of BCAA (Figure 6C). In contrast, in the soleus muscle,
treatmentwithDEX alone or DEXplus BCAAonlymarginally influ-
enced mTOR activity and the gene expression profile, if at all
(Figures 6B and 6C).
In this glucocorticoid-induced muscle atrophy rat model, there
was a decrease in the body weight of the DEX, DEX plus BCAA,
and DEX plus BCAA plus rapamycin groups (Figure 7A). The
DEXplusBCAAgroup revealed a significant restorationofmuscle
strength as determined by a grip test and the weight of the
gastrocnemius muscle when compared with DEX group (Figures
7B and 7C). Histological examination of the gastrocnemius
muscle demonstrated typical type II fiber-dominant atrophy in
the DEX group; however, the DEX plus BCAA group showed
less impairment in the gastrocnemius muscle that was repre-
sented by the prevention of type II fiber loss. Semiquantitative
analysis using cross-sectional area (CSA) analysis of myofibers
strongly supported this notion; the leftward shift in myofiber sizeetabolism 13, 170–182, February 2, 2011 ª2011 Elsevier Inc. 175
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Figure 4. KLF15-Mediated Modulation of BCAA Metabolism and Myofiber Size
(A) Time course of mRNA expression of KLF15 and BCAT2 in rat gastrocnemius after intraperitoneal DEX-injection (n = 5).
(B) KLF15-dependent activation of rat BCAT2 promoter-reporter gene expression in L6 myoblasts (n = 5).
(C) Diminished GR-dependent activation of rat BCAT2 promoter-reporter gene by knockdown of KLF15 in L6 myoblasts (n = 5).
(D) GR-dependent activation of BCAT activity in rat gastrocnemius. Rats were treated with RU486 and/or DEX for the indicated time periods (left) or 6 hr (right) and
subjected to BCAT activity measurement as described in the Supplemental Information (n = 5).
(E) KLF15-dependent activation of BCAT activity (n = 5).
(F) Effects of ectopic KLF15 on intracellular amino acid concentrations. L6 myotubes were infected with Ad-KLF15 for 2 days, cultured in amino acid-deprived
DMEM for 24 hr, and subjected to quantification of intracellular amino acids as described in the Supplemental Information (n = 3).
(G) Effects of KLF15 and BCAA on mTOR activity and myotube diameter. C2C12 myotubes were infected with GFP-expressing adenovirus and Ad-KLF15 for
2 days and further cultured in amino acid-deprived DMEM supplemented with or without 10 mM BCAA cocktail for 24 hr. Left, representative immunoblots
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Crosstalk between GR and mTOR in Skeletal Musclewas observed in the DEX group, but not in the DEX plus BCAA
group. In contrast, there was no significant difference in the size
of slow type I fibers among the three treatment groups.Moreover,
the therapeutic effects of BCAA were inhibited by rapamycin
(Figures 7B–7E). Therefore, we conclude that the administration
of BCAAelicitsmTORactivation and intervenes inGR-dependent
catabolic transcriptional regulation to ameliorate DEX-induced
muscle atrophy.
DISCUSSION
In skeletal muscle, we suggested that GR activates a secondary
transcription network driven by KLF15; that the promoter regions
of atrogin-1 and MuRF1 contain KLF15 binding sites as well as
those of FoxOs; and that KLF15 induces the expression of these
atrogenes. Although the molecular mechanism remains elusive,
the functional cooperativity of GR, FoxOs, and KLF15 in the
expression of the atrogenes may represent the molecular basis
for the involvement of GR in muscle atrophy associated with
a number of pathological conditions including diabetes and
sepsis. From the metabolic viewpoint, these GR-driven tran-
scriptional cascades appear to be relevant for providing rapid
and integrated cues toward muscle breakdown and nutrient
supply from muscle to other organs, i.e., to the liver, under
stressful conditions associated with excess levels of
glucocorticoids.
BCAT2 catalyzes the initial step for BCAA degradation, and
BCAT2 activity is a critical determinant of cellular BCAA content
in skeletal muscle; mice with systemic inactivation of BCAT2
gene are reported to have approximately ten times or higher
concentrations of plasma BCAA (She et al., 2007). We demon-
strated that BCAA content was decreased with a reciprocal
increase in alanine levels in L6 myotubes after the exogenous
expression of KLF15 (Figure 4F). Although it is generally known
that BCAA is supplied via protein breakdown during skeletal
muscle atrophy (Wagenmakers, 1998; Yu et al., 2010), it was
reported that net increase in muscle BCAA concentrations after
glucocorticoid treatment (150% increase compared to
control) were strikingly lower than those of diabetic rats
(400% increase compared to control) (Aftring et al., 1988;
Hundal et al., 1991). This difference in BCAA concentrations is
most likely to be due to increased BCAT2 activity in glucocorti-
coid-treated rats. The glucocorticoid-driven GR-KLF15-BCAT2
axis may negatively modulate the intracellular availability of
BCAA and result in a negative impact on mTOR function in skel-
etal muscle. Indeed, exogenous KLF15 increased mRNA
expression of the atrogenes and BCAT2 and decreased
mTOR activity and BCAA concentrations in cultured myotubes
(Figures 4E–4G). Moreover, the introduction of KLF15
decreased myofiber size in cultured myotubes and causedand quantified band densities of S6K1 and p-S6K1(T389) relative to GAPDH (n =
quantified diameters of the myotubes (500 < n < 510).
(H) Effects of ectopic KLF15 expression on mTOR activity and myofiber cross-se
quantified band densities (n = 5). Right, immunostaining for type IIB myosin heavy
in right photographs), and type IV collagen (green) of transverse cryosections. CS
frequency histograms (500 < n < 510).
(A–H) Error bars show SD. *p < 0.05, zp < 0.05 versus vehicle-treated rats. yp < 0
Cell Matrophy in the tibialis anterior muscle, even in the absence of
glucocorticoids (Figures 4G and 4H). Therefore, we may
conclude that KLF15 is a crucial GR target gene acting as
a catabolic modulator of skeletal muscle.
In addition to the KLF15-BCAT2 axis, it should be noted that
a number of glucocorticoid-induced products can repress
mTOR activity in skeletal muscle cells. Among others, myostatin
(Ma et al., 2001; Gilson et al., 2007) and REDD1 (Figure S1)
(DeYoung et al., 2008) are direct targets of GR. Moreover, atro-
gin-1 was recently reported to inhibit S6K1 activity via eIF3f
(Csibi et al., 2010). Therefore, it is likely that the mTOR system
is negatively regulated by a variety of factors in the presence
of excess glucocorticoids in a distinct fashion. Given that the
glucocorticoid-GR axis is a major catabolic regulator for homeo-
static control (Munck et al., 1984), this multimodal repression of
mTOR via the GR axis appears to be rational. In any case, this
type of negative mTOR modulation is not reported in other types
of muscle atrophy, and may be a striking feature in glucocorti-
coid-induced muscle atrophy. Interestingly, muscle-specific
inactivation of mTOR was reported to exacerbate the myopathic
features of type I and type II fiber-rich muscles in a distinct
fashion; type I fiber-rich muscles showed prominent dystrophic
features with less impact on muscle mass and CSA compared
to type II fiber-rich muscles, and a decrease in muscle mass
and CSA are characteristic of type II fiber-rich muscles with
less dystrophic appearance (Bentzinger et al., 2008; Risson
et al., 2009). Therefore, we speculate that type II fiber-rich glyco-
lytic muscles have an evolutionally preserved role for the storage
of nutrients under the control of the glucocorticoid-GR axis and
that the GR-triggered gene expression program is a purposeful
and efficient compensatory mechanism for nutrient supply
from those muscles.
An important question is how the GR-driven proteolytic
cascades can be shut down when necessary in skeletal muscle.
We clearly demonstrated that mTOR activation negatively
modulated GR-mediated transcription. Given that the effect of
mTOR is rapamycin sensitive, the involvement of mTORC1 is
strongly indicated in this interaction. The role of the mTOR
pathway in the determination of glucocorticoid sensitivity has
not yet been highlighted, except in certain hematologic malig-
nancies (Beesley et al., 2009; Gu et al., 2008; Yan et al.,
2006a). It was postulated that the treatment of cultured cells
with FK506 or rapamycin enhances glucocorticoid-inducible
reporter gene expression, most possibly via their interaction
with heat shock proteins and the promotion of the ligand-
dependent nuclear entry of GR (Ning and Sanchez, 1993). In
contrast, we documented that rapamycin, without any alteration
in the cytoplasmic-nuclear distribution of GR, increased GR
recruitment onto the promoter (Figures 5E and 5F), and these
effects were not reproduced by FK506 (data not shown).5). Right, representative fluorescent microscopic images of the myotubes and
ctional area (CSA) in rat tibialis anterior. Left, representative immunoblots and
chain (MHC IIB, red in left photographs), type I myosin heavy chain (MHC I, red
A distribution of MHC IIB fibers (left) and MHC I fibers (right) are presented as
.05 versus mock-transfected cells.
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Figure 5. Negative Regulation of GR-Mediated Transcription by mTOR
(A) qRT-PCR analysis of L6 myotubes treated with DEX and rapamycin (Rapa) for 24 hr.
(B) Attenuation of GR-dependent reporter gene expression bymTOR. L6myoblasts were transfectedwith rKLF15 promoter-LUCor GRE-LUC, with or without the
expression plasmid for a constitutive active Rheb (RhebS16H), and treated with DEX and rapamycin for 18 hr.
(C) Effects of IGF-1 on mTOR activity and GR-dependent reporter gene expression. L6 myoblasts were transfected with GRE-LUC and cultured in amino acid-
deprivedDMEM (lanes 1–4) or normal DMEM (lanes 5–8) in the presence or absence of IGF-1 and/or DEX for 9 hr. Top, luciferase activities. Bottom, representative
immunoblots.
(D) Effects of DEX, BCAA, cycloheximide, and rapamycin on GR-dependent reporter gene expression. L6 myoblasts were transfected with GRE-LUC and
cultured in amino acid-deprived DMEM in the presence or absence of 10 mM BCAA cocktail, cycloheximide, rapamycin, and DEX for 6 hr.
(E) Effects of DEX, BCAA, and rapamycin on protein levels and subcellular localization of GR. L6 myotubes were cultured in amino acid-deprived DMEM in the
presence or absence of DEX, 10 mM BCAA cocktail, and rapamycin for 30 min. Representative immunoblots of the nuclear extracts (NE), cytoplasmic fractions
(CF), and whole-cell extracts (WCE) are shown (n = 3).
(F) Effects of rapamycin on DEX-dependent recruitment of GR onto target gene promoters. L6 myotubes were treated with 1 mM DEX and rapamycin for 2 hr
(for KLF15) or 20 min (for REDD1) and processed for ChIP assays.
(G and H) Effects of ectopic expression of RhebS16H onmTOR activity and DEX-mediatedmRNA expression. AAV-RhebS16H was infected to rat tibialis anterior
for 7 days. (G) Representative immunoblots (n = 7). (H) qRT-PCR analysis of the muscles from the rats 6 hr after intraperitoneal injection with DEX.
(A–D, F, and H) Error bars show SD (n = 5). *p < 0.05, xp < 0.05 versus ChIP with normal IgG, {p < 0.05 versus vehicle-treated rats.
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Figure 6. In Vivo Activation of mTOR and
Attenuation of GR-Mediated Transcription
after Programmed Administration of BCAA
(A) Time course of mTOR activity in rat gastrocne-
mius after BCAA administration. Representative
immunoblots are shown (n = 5).
(B–D) Effects of DEX, BCAA, and rapamycin on
mTOR activity; mRNA expression of atrophy-
related genes; and GR recruitment onto the target
gene promoters. Rats were treated with DEX,
BCAA cocktail, and rapamycin for 5 days as
described in the Supplemental Information. (B)
Representative immunoblots (n = 17). L6 myo-
tubes cultured in normal DMEM and in amino
acid-deprived DMEM (a.a.) for 1 hr were served
as controls. (C) mRNA expression of atrophy-
related genes. (D) Recruitment of GR onto its
target genes. ChIP was performed using anti-GR
antibody.
(C and D) Error bars show SD (n = 17). *p < 0.05,
zp < 0.05 versus vehicle-treated rats, xp < 0.05
versus ChIP with normal IgG.
Cell Metabolism
Crosstalk between GR and mTOR in Skeletal MuscleTherefore, the mTOR-mediated inhibition of GR in skeletal
muscle is likely to be due not to the modulation of its chaperone
activity but to its intervention in the access of GR to target DNA.
It is becoming apparent that mTOR is intimately involved with
the transcriptional apparatus in concert with a variety of tran-
scription factors and cofactors (Cunningham et al., 2007). Since
mTOR is reported to dock in the nucleus in association with, for
example, PML (Bernardi et al., 2006), it would be of particular
interest to identify such a factor that tethers GR and mTOR in
the nucleus.Cell Metabolism 13, 170–182In skeletal muscle, this nutrition
sensor-driven inhibition of GR function
may be one of the mechanisms by which
nutrients modulate the internal cellular
milieu. Intriguingly, GR-mediated tran-
scription was not repressed by insulin/
IGF-1 under normal culture conditions,
but did so when amino acids were
deprived from the culture media (Fig-
ure 5C). This indicates that mTOR may
be constitutively activated to a certain
extent by nutrients and growth factors
to protect cells from GR-driven catabo-
lism in skeletal muscle. Under fasting
conditions, however, blood concentra-
tions of insulin/IGF-1 are low, and gluco-
corticoids may be allowed to efficiently
drive the catabolic atrophy program for
nutrient supply. Thus, our hypothesis
may provide an insight into how muscle
cells critically determine their volume
after sensing endocrine hormones and
the nutritional conditions for homeostatic
regulation. In this context, GR-mTOR
crosstalk might be a key for creating an
interdisciplinary research area that
bridges nutrition and medicine.The biochemical rationale for the usage of BCAA as a thera-
peutic tool in glucocorticoid-induced muscle atrophy is that
BCAA increases the association between Rheb and mTOR
and, at least in part, mimics the effect of Rheb overexpression
(Sancak et al., 2010). In our model, BCAA administration
repressed mRNA expression of almost all GR-regulated genes
(Figure 6C). ChIP analysis strongly supported the notion that
BCAA administration inhibited GR recruitment onto the
promoters of its target genes (Figure 6D). Moreover, these
effects of BCAA were efficiently counteracted by rapamycin., February 2, 2011 ª2011 Elsevier Inc. 179
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Figure 7. Restoration of Muscle Fiber Mass
and Strength by mTOR Activation in DEX-
Induced Skeletal Muscle Atrophy Model
(A–E) Effects of DEX, BCAA, and rapamycin on
body weight (A), grip strength of forearms (B),
muscle weight (C), muscle pathology (D), and
CSA of skeletal muscle fiber (E). Rats were treated
with DEX, BCAA, and rapamycin for 5 days as
described in the Supplemental Information. (A)
Time course of body weight (n = 15). (B) Grip
strength of forearms at 5 hr after DEX injection
on the day 5 (47 < n < 51). (C) Weight of gastrocne-
mius and soleus at 6 hr after DEX injection on the
day 5 (n = 15). (D) Immunostaining for MHC IIB
(red in left photographs), MHC I (red in middle
and right photographs), and type IV collagen
(green) of transverse cryosections. (E) CSA distri-
bution of MHC IIB fibers (gastrocnemius) and
MHC I fibers (gastrocnemius and soleus) pre-
sented as frequency histograms (500 < n < 510).
(F) Schematic model of mutual crosstalk between
catabolic processes and anabolic processes in
skeletal muscle.
(A–C) Error bars show SD (A and C) or SEM (B).
*p < 0.05, zp < 0.05 versus vehicle-treated rats.
Cell Metabolism
Crosstalk between GR and mTOR in Skeletal MuscleTherefore, we are convinced that the therapeutic effects of
BCAA could, at least in part, be ascribed to GR inhibition by
the BCAA-mediated activation of mTOR. BCAA administration
also resulted in the decreased mRNA expression of autoph-
agy-related genes (Figure 6C), indicating that this therapeutic
regimen repressed the vicious circuit connecting the initial
induction of GR-triggered gene expression to degradation and
atrophy. Of course, we cannot rule out other mechanisms for
the effects of BCAA, including the non-GR-mediated repression
of atrophy and/or autophagy, and further studies are clearly
needed to clarify this issue.
There are conflicting results concerning the biological effects
of BCAA, e.g., the overactivation of amino acid-dependent
mTOR-mediated signaling can lead to the inhibition of the180 Cell Metabolism 13, 170–182, February 2, 2011 ª2011 Elsevier Inc.proximal part of the insulin signaling
pathway (Um et al., 2006). Moreover, in
obese humans, BCAA in association
with a high-fat diet is linked to the eleva-
tion of insulin resistance (Newgard et al.,
2009). On the other hand, it is suggested
that an increase in type II fibers in obese
mice may reduce fat mass and improve
metabolic parameters (Izumiya et al.,
2008). Therefore, it is necessary, for the
validation of BCAA therapy, to evaluate
the influence of long-termBCAA adminis-
tration on various metabolic parameters.
In conclusion, we revealed that GR and
mTOR act as catabolic and anabolic liai-
sons for skeletal muscle metabolism,
respectively, and these molecules
interact with each other at multiple levels.
This issue would be of particular impor-
tance to understand the molecular mech-anism underlying the regulation of the volume andmetabolism of
muscle and for the development of treatments for glucocorti-
coid-induced and wasting disorder-related skeletal muscle
atrophy.
EXPERIMENTAL PROCEDURES
Rats
All animal experiments were approved by the institutional committee and
conducted according to the institutional ethical guidelines for animal experi-
ments. Rapamycin, RU486, the BCAA cocktail, and DEX administration were
performed as described in the Supplemental Information. Excised tissues
were snap frozen in isopentane cooled by liquid nitrogen, and crushed using
Cryo-Press (Microtec, Funabashi, Japan) prefrozen in liquid nitrogen, or
processed to serial 10 mm transverse cryostat sections.
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L6 rat myoblasts, C2C12 mouse myoblasts, and COS-7 cells were obtained
from American Type Culture Collection (Manassas, VA) and maintained in
DMEM supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA). Culture conditions for myotube formation, drug treatment, and amino
acids deprivation are described in the Supplemental Information.In Silico Promoter Analysis
Putative FoxO1- and FoxO3-binding sequences, as well as putative GREs
which are conserved between rat and human genomes, were searched for
in the genomic regions (5000 to +2000) of KLF15, REDD1, atrogin-1, and
MuRF1 using rVISTA 2.0 as described in the Supplemental Information.
KLF15-binding sequences (see the Supplemental Information) were searched
for in the promoters of rat atrogin-1 (4141 to +1191) and MuRF1 (3223
to +1547) genes.Chromatin Immunoprecipitation Assay
Cells or crushed tissues were treated with 1% formaldehyde in PBS for 10 min
at 37C, incubated in 125 mM glycine for 5 min, resuspended in buffer S
(50 mM Tris [pH 8.0], 1% SDS, 10 mM EDTA) supplemented with 1 mM
DTT, 100 nMMG132, and protease and phosphatase inhibitor cocktail (Naca-
lai Tesque, Kyoto, Japan), and incubated at 10C for 10 min. Samples were
sheared to an average size of 500 bp by sonication. Lysates corresponding
to 2 3 106 cells or 200 mg of crushed tissues were diluted 10-fold in buffer
D (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris [pH 8.1],
167 mM NaCl) supplemented with 100 nM MG132, and protease and phos-
phatase inhibitor cocktail, and incubated with 5 mg of antibodies listed in the
Supplemental Information at 4C for 18 hr. Protein A or G agarose/salmon
sperm DNA (Millipore, Billerica, MA) was added and further incubated at 4C
for 1 hr. Precipitated DNA were quantified as described in the Supplemental
Information.Indirect Immunofluorescent Staining and Fluorescence Imaging
Muscle cryosections were treated with 0.1% Triton X-100, blocked with 5%
goat serum/1% BSA in PBS, and incubated with antibodies listed in the
Supplemental Information. After washing with PBS, specimens were
incubated with secondary antibodies labeled with Alexa Fluor 488 or Alexa
Fluor 568 (Invitrogen, 1:1000) and analyzed as described in the Supplemental
Information. For imaging cultured myotubes, GFP was expressed in myotubes
by infecting 10 multiplicity of infection of Ax1CAgfp (RIKEN DNA Bank, Tsu-
kuba, Japan).Statistical Analysis
Datawere analyzedwith Student’s t test for unpaired data. P values below 0.05
were considered statistically significant. Graphs represent means ± SD or
means ± SEM as specified in each figure legend.SUPPLEMENTAL INFORMATION
Supplemental Information include one figure, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
at doi:10.1016/j.cmet.2011.01.001.ACKNOWLEDGMENTS
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